GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018
November 29 2018 - 9:15AM
Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it
will host and webcast an investor/analyst meeting and update at the
60th American Society of Hematology (ASH) Annual Meeting
in San Diego, on December 3 at 6 a.m. PT. Daniel J. DeAngelo,
MD, PhD, Director of Clinical and Translational Research, Adult
Leukemia Program, Dana-Farber Cancer Institute/Brigham and Women’s
Hospital, Associate Professor of Medicine, Harvard Medical School,
who served as lead investigator of the GlycoMimetics’ recently
completed Phase 1/2 clinical trial of uproleselan in acute myeloid
leukemia patients, will recap and provide perspective on his
December 2 oral presentation at the ASH meeting, highlighting the
trial’s findings. GlycoMimetics management will review additional
posters from the ASH meeting.
The investor/analyst event will be webcast beginning at 6:15
a.m. PT. The dial-in number for the event is (844) 413-7154
(U.S. and Canada) or (216) 562-0466 (international) with
passcode 9779654. To access the live audio webcast, or the
subsequent archived recording, visit the “Investors - Events &
Presentations” section of the GlycoMimetics website
at www.glycomimetics.com. The webcast will be recorded and
available for replay on the GlycoMimetics website for 30
days following the call.
Investors/analysts are requested to pre-register for the private
in-person event at IR@glycomimetics.com. The event will be held at
Hard Rock Hotel San Diego in the Celebrate Room, 207 Fifth Avenue,
San Diego. On-site inquiries will be handled by Shari Annes, (650)
888-0902, by text or phone.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly owned drug candidate, uproleselan, an
E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial
as a potential treatment for AML and is currently being evaluated
in a company-sponsored Phase 3 trial in relapsed/refractory
AML. The U.S. Food and Drug Administration granted uproleselan
breakthrough therapy designation for the treatment of adult
AM) patients with relapsed/refractory disease.
GlycoMimetics has also completed a Phase 1 clinical trial with
a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181129005413/en/
Investor Contact:Shari AnnesPhone: 650-888-0902Email:
sannes@annesassociates.com
Media Contact:Jamie Lacey-MoreiraPhone:
410-299-3310Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Sep 2023 to Sep 2024